News

OliX CEO Dong-ki Lee said:  "The approval of this CTA marks an important milestone for OliX's RNAi therapeutic development, by demonstrating that OliX has met and qualified against the

The company decided to not to pursue the re-examination procedure, which the firm initially requested for the MAA of masitinib in the treatment of ALS. The firm has determined that

Under the terms of the agreement, CENTOGENE will collaborate with Aldeyra to globally identify patients with Sjögren-Larsson Syndrome (SLS) and to understand the clinical spectrum of this disease.

Top line results from the study announced last month revealed the treatment missed its primary endpoint. Howevr, additional data analysis showed that in the European cohort, Lupuzor had a statistically significant 71.1% response rate against

The study is a combined Phase I and II study in approximately 40 patients to be conducted at specialist centres at the University of California, San Francisco and

The phase I MMY2036 study of daratumumab plus JNJ-63723283, an anti PD-1 antibody in patients with multiple myeloma, will also be terminated. The Data Monitoring Committee (DMC) has

The agreement outlines the legal terms under which Beactica and Sanofi collaborate on the characterization of interactions between novel therapeutics and their target proteins. As part of the

The phase III pacific trial is a randomized, double-blinded, placebo-controlled, multi-center trial of Imfinzi in patients with unresectable Stage III NSCLC whose disease has not progressed following platinum-based chemotherapy concurrent with

Zessly is approved for use in all indications of the reference medicine including rheumatoid arthritis, adult Crohn's disease, pediatric Crohn's disease, adult ulcerative colitis, pediatric ulcerative colitis, ankylosing spondylitis,